InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Burgess Michael F., Responsable de la Recherche et Développement. Insider active across 2 companies, notably SpringWorks Therapeutics, Inc.. Aggregated, 6 reports have been logged. History available since 1 June 2021. The latest transaction was filed on 18 July 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations6 total
●
3,103 shares@ US$28.4763.9% of flowCommon StockSEC:0001104659-22-081241:0
●
2,672 shares@ US$19.6136.1% of flowCommon StockSEC:0001104659-22-077447:0
15,674 sharesCommon StockSEC:0001104659-22-002741
15,674 sharesCommon StockSEC:0001104659-22-002741:0
27,500 shares0Common StockSEC:0001104659-21-075168:0
27,500 shares0Common StockSEC:0001104659-21-075168
6 of 6 declarations
About Burgess Michael F.
Michael F. Burgess is the Head of Research & Development at SpringWorks Therapeutics, Inc. He leads the company's innovation efforts, which focus on developing therapeutic treatments. Burgess plays a crucial role in research strategy, contributing to the advancement of drug development projects. His expertise is vital in ensuring the success of the company's research initiatives.
